The introduction of combined antiretroviral therapy (cART) led to significant increases in the survival and quality of life of human immunodeficiency virus (HIV)-infected patients. However, the life expectancy of successfully treated HIVinfected subjects has been estimated to be 10 years lower than that of the general population [1] . It is known that cART is not able to normalize all immune-related parameters [2] , even though full normalization of CD4 + T-cell counts can be achieved after persistent viral suppression [3] . In early 1998, an association between the level of soluble CD14 (sCD14) and HIV disease progression and associated clinical events was reported [4] , and recently, sCD14 levels have been associated with mortality among HIV-infected subjects receiving cART [5] . We have reported that the sCD14 level but not the lipopolysaccharide (LPS) level was independently associated with markers related to progression of HIV disease, further supporting the clinical importance of sCD14 [6] . sCD14 is a marker for monocyte/macrophage activation and a mediator of bacterial LPS action [7] . Cross-sectional studies in different scenarios of HIV-treated infection have shown a higher sCD14 level in HIV-infected subjects, compared with healthy subjects [8, 9] , although only a few longitudinal studies have explored the effect of a short-term cART on sCD14 level, with controversial results [10, 11] . To our knowledge, only 1 report analyzed the effect of long-term cART exposure on sCD14 level, but the immunovirological conditions of the study population at cART initiation were not considered [12] . The aim of this study was to analyze the effect of a long-term suppressive cART regimen on the sCD14 level.
SUBJECTS AND METHODS

Study Design
We analyzed serum samples from 85 consecutive cART-naive subjects with asymptomatic HIV infection who visited the Infectious Disease Unit of Virgen del Rocío University Hospital from April 1997 to April 2012. Available serum samples from HIV-infected subjects who initiated suppressive cART (ie, those with HIV-1 RNA levels of ≤40 copies/mL 3 months after the onset of cART) were analyzed at baseline (ie, before cART initiation; n = 85 samples) and after 1 year of suppressive cART (n = 85 samples). We also analyzed subjects with available samples after 5 years of suppressive cART (n = 43 samples). These samples were obtained from the HIV BioBank of the Spanish AIDS Research Network [13] . As reference values, we included samples from 18 HIV-negative agematched donors who were ≤50 years old (young controls) and from 43 HIV-negative donors who were >50 years old (elderly controls). No control subjects had symptoms, none were receiving any treatment that could influence their immune status, and none had clinical data of active infections or neoplasias. The study was approved by the ethics review board of the Virgen del Rocío University Hospital, and all study subjects provided written informed consent.
Laboratory Measurements
Absolute CD4 + T-cell numbers were determined in fresh blood, using an Epics XL-MCL flow cytometer (BeckmanCoulter, California, USA count at baseline) and sCD14 level at baseline and the values at the 1-year and 5-year time points were assessed using a bivariate linear regression analysis. Variables determined to be statistically significant (P < .1) in the bivariate analysis were included in a multivariate analysis, using a step-forward procedure. The regression coefficient (B) and 95% confidence interval (CI) for B were estimated for this model. Statistical analysis was performed using SPSS, version 17 (SPSS [Chicago, IL]). A P value of < .05 was considered statistically significant.
RESULTS
Characteristics of the Study Subjects
Eighty-five HIV-infected subjects, 18 young controls, and 43 elderly controls were included in this study. All subjects were white. The baseline characteristics of HIV-infected subjects and control groups are shown in Table 1 . The sCD14 level was analyzed at baseline for HIV-infected patients and controls and at 1 and 5 years for HIV-infected patients. During this period, the median increase in CD4 + T-cell count was 171 ) at 5 years. For HIV-infected subjects, characteristics for the 85 subjects at baseline were not significantly different from those for the 43 subjects who remained enrolled at 5 years (data not shown).
Long-Term cART Did Not Normalize the sCD14 Level in HIVInfected Subjects
When compared to young controls, HIV-infected subjects displayed a significantly higher sCD14 level at baseline, at 1 year, and at 5 years (P < .001 for all comparisons). Furthermore, the sCD14 level was neither reduced nor normalized at 1 year and 5 years, compared with the sCD14 level at baseline, because no significant changes were observed between time points (P = .152 and P = .381, by the Wilcoxon text, at 1 and 5 years, respectively; Figure 1A ). Moreover, HIV-infected subjects displayed a significantly higher sCD14 level at all time points, compared with elderly controls (P < .001 for all comparisons). The elderly controls also displayed a higher sCD14 level than the young controls (P = .014; Figure 1A ).
Influence of Baseline Immunovirological Status on sCD14 Level
We explored potential associations between sCD14 level and (n = 59). Globally, when compared to the control groups, both subgroups of HIV-infected subjects had a higher sCD14 level at baseline, at 1 year, and at 5 years (P < .001 for all comparisons, except for the high CD4 + T-cell count group at 1 year vs the elderly controls [P = .094]; Figure 1D and 1E). Interestingly, only the low CD4 + T-cell count group had a reduction in sCD14 level at 5 years (P = .026, by the Wilcoxon test; P = .530 for the high CD4 + T-cell count group; Figure 1D and 1E).
Interestingly, as we also found in a previous report [6] , the baseline sCD14 level was significantly higher in the low CD4 + T-cell count group, compared with the high CD4 + T-cell count group (P < .001). In a similar analysis, we found that the baseline HIV load did not influence the changes in sCD14 level (data not shown).
Influence of cART Type on sCD14 Level
HIV-infected subjects were categorized into 3 subgroups according to the composition of their cART regimen (Table 1) . Contrary to findings for the other groups, subjects receiving maraviroc-containing cART displayed similar baseline and 1-year sCD14 levels, compared with young controls (P > .05 for all comparisons; Supplementary Figure 1A) . 
DISCUSSION
In this longitudinally designed study, we report that long-term receipt of suppressive cART (for up to 5 years) neither reduced nor normalized the level of sCD14, which is a soluble marker of inflammation and innate immune activation and has been associated with all-cause mortality in HIV infection [4] [5] [6] . First, it is important to note that our study population included subjects for whom the time since diagnosis was short, who initiated cART early, and who received virologically successful long-term regimens, suggesting that serious damage responsible for the elevated sCD14 level occurs very early during HIV infection and persists despite viral suppression and restoration of CD4 + T-cell count. Second, the sCD14 level remained even higher in treated patients than in HIV-negative elderly controls who were, on average, >30 years older. Hence, one could speculate that the sCD14 level could be another b Includes male-male sex and heterosexual sex.
c "PI-sparing cART" denotes cART without PIs that may contain either nucleoside reverse-transcriptase inhibitors or nonnucleoside reverse-transcriptase inhibitors, "PI-containing cART" denotes cART including PIs and nucleoside reverse-transcriptase inhibitors or nonnucleoside reverse transcriptase inhibitors, and "MVC-containing cART" denotes cART that includes MVC and PIs.
immunosenescence-associated marker, like those present in treatment-naive HIV-infected subjects with a short period of infection [14] . Some longitudinal analyses considering the short-term effect of cART exposure found that the sCD14 level was not normalized [10, 11] , although 2 years of treatment yielded a significant reduction [10] . To our knowledge, only 1 longitudinal analysis has previously reported the effects of long-term cART exposure, showing that the sCD14 level declined with exponential decay after a median follow-up time of 6.5 years, although the authors were unable to predict whether, beyond the study period, the sCD14 level would plateau [12] . Our results argue in favor of a plateau in sCD14 level, which was elevated in HIV-infected subjects after cART, compared with levels for both young and elderly controls.
Potential mechanisms that could explain a plateau in the sCD14 level during HIV infection include (1) persistent microbial translocation favored by persistent GALT-associated damage; (2) residual HIV proteins in virologically suppressed patients that could directly activate the innate immune system; (3) chronic alterations of the function of monocytemacrophages, including increased secretion of sCD14; and (4) subclinical reactivation of other persistent infections (eg, those due to Leishmania organisms or herpesvirus) favored by HIVassociated immunodeficiency.
Both baseline CD4 + T-cell count and HIV viremia could be potentially related to the sCD14 level. Consistent with other reports [8, 9] , we observed a negative association between sCD14 level and CD4 + T-cell count and a positive association between sCD14 level and HIV load. In light of these results, it is important to consider the time of cART initiation, because delayed treatment initiation is likely to be associated with increased damage beyond that associated with sCD14, the consequences of which are unknown. Other authors have also considered HIV-infected subjects with severe CD4 + T-cell lymphopenia at cART initiation and found that, after 1 year of Figure 1 . Influence of immunovirological parameters on the level of soluble CD14 (sCD14). A, sCD14 levels in all human immunodeficiency virus (HIV)-infected subjects studied at baseline (ie, before combined antiretroviral therapy [cART] initiation), 1 year after cART initiation, and 5 years after cART initiation and in control groups of young and elderly individuals. Note that, when the 2 potential outliers in the young control group were omitted, differences between young and elderly control groups became less significant (P = .055). Interestingly, one of these outliers had the highest CD4 + T-cell count, but the other value was not available. B and C, The relationships between sCD14 level and CD4 + T-cell count (B) or HIV load (C) at baseline were evaluated by the Spearman ρ correlation coefficient test. D, The sCD14 level in HIV-infected subjects with a low baseline CD4 + T-cell count (≤200 cells/mm 3 ), at baseline, at 1 year, and 5 years, and in control groups. E, The sCD14 level in HIV-infected subjects with a high baseline CD4 + T-cell count (>200 cells/mm 3 ), at baseline, 1-year cART, 5-years cART, and control groups. The Wilcoxon test (dashed line) was used to analyze differences during the follow-up period (ie, at 1 and 5 years after cART initiation). The Mann-Whitney U test (solid line) was used to compare the level of sCD14 between HIV-infected subjects and healthy subjects. * P < .05 and **P < .001. therapy, the subjects maintained an increased sCD14 level [11] . Similarly, we found no changes in sCD14 level after a median duration of suppressive cART of 3.5 years in HIVinfected populations with a low baseline CD4 + T-cell count [15] . However, subjects who started cART with a high CD4 + T-cell count, such as those who received maraviroc-containing cART, showed sCD14 levels similar to those of the HIVnegative control group. This may explain why we did not observe the potential immunomodulatory effect of this CCR5 antagonist. However, we cannot exclude such effect in highly immunodeficient patients starting a maraviroc-containing regimen. Our study has several limitations. First, there was a low number HIV-infected patients who were followed up at 1 year. This number was even lower at the 5-year time point, although the missing data corresponded to patients who had not reached the 5-year time point. Also, subjects eligible for enrollment as control subjects were scarce, complicating the achievement of statistical power. Moreover, we cannot exclude the possibility that the sCD14 level could normalize after a longer period of cART. Nevertheless, our results strongly recommend early initiation of cART to control immune damage beyond sCD14 levels, and they point to the necessity of searching for complementary therapies to treat the activated/ inflamed status associated with chronic HIV infection.
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